Transplant Focus Growth Veloxis specializes in transplant focused therapies and is advancing pegrizeprument for multiple transplant indications, signaling a strong sales angle with transplant centers nephrologists and immunosuppression decision makers. The company s ongoing development and its alignment with Asahi Kasei create a platform for institutional partnerships training programs and comprehensive support for adoption of new maintenance therapies.

Global Partnership Backbone Asahi Kasei s ownership provides global regulatory manufacturing and commercial capabilities to accelerate market access. This opens opportunities for international distribution deals co promotion arrangements and supply chain partnerships with transplant centers worldwide.

Asset Expansion Opportunity Veloxis has obtained worldwide rights to develop and commercialize pegrizeprument for all transplant indications with ongoing data presentations at major conferences. This creates business development opportunities for licensing discussions co development deals and partnerships with contract research or manufacturing organizations to accelerate development timelines and scale manufacturing if needed.

Patient Community Access Veloxis engages patient networks through Donate Life North Carolina and transplant focused events offering channels for patient recruitment education and advocacy in payer conversations. Leverage these relationships to support trial enrollment patient support programs and payer outreach to secure formulary access for new maintenance therapies.

Data Driven Readiness The company employs analytics and CRM tools including Power BI Salesforce IQVIA and Oracle indicating readiness for data driven market access payer analytics and outcomes research. This enables business development to propose value based contracting real world evidence generation and tailored market access strategies for transplant centers and health systems.